Brief: Chemomab Therapeutics Receives FDA Fast Track Designation For Cm-101 For The Treatment Of Primary Sclerosing Cholangitis

Chemomab Therapeutics

15/11/2023 12:07

Nov 15 (Reuters) - Chemomab Therapeutics Ltd  CMMB.O :
    * CHEMOMAB THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION
FOR
CM-101 FOR THE TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS
    * CHEMOMAB THERAPEUTICS - CM-101'S PHASE 2 SPRING TRIAL IN
PSC IS
ADVANCING TOWARDS COMPLETION OF ENROLLMENT WITH TOP-LINE READOUT
EXPECTED IN 2H 2024

Source text for Eikon:  ID:nPn7ntDC3a 
Further company coverage:  CMMB.O 

 ((Reuters.Briefs@thomsonreuters.com))